Clinical trial
Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate Cancer
NCT04812366
Study timeline
Study start (actual)2021-09-21Date precision: day
Registry last updated2026-08-14
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Prostate Cancerunresolved
Interventions
DocetaxelDRUG · verified · RxNorm: docetaxel
AtezolizumabDRUG · verified · RxNorm: atezolizumab
CapivasertibDRUG · verified · RxNorm: capivasertib
Sponsors & collaborators
University of British Columbialead sponsor
Janssen Inc.collaborator
University Health Network, Torontocollaborator
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT04812366 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.